相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer
Sahar K. Hegazy et al.
LIFE SCIENCES (2022)
Mechanisms of cancer cell death induction by paclitaxel: an updated review
Shuang Zhao et al.
APOPTOSIS (2022)
Senescence of Tumor Cells in Anticancer Therapy-Beneficial and Detrimental Effects
Wiktoria Monika Piskorz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Managing Cancer Drug Resistance from the Perspective of Inflammation
Shuaijun Lu et al.
JOURNAL OF ONCOLOGY (2022)
Breast cancer: an up-to-date review and future perspectives
Ruoxi Hong et al.
CANCER COMMUNICATIONS (2022)
Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications
Kathrine S. Rallis et al.
ANTICANCER RESEARCH (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
S. Mansoori et al.
SCIENTIFIC REPORTS (2021)
Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death
Jakeb S. S. M. Petersen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Safety and Tolerability of Mebendazole in Infants Under 1 Year of Age
Yaara Kahan et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)
Microtubule-targeting agents and their impact on cancer treatment
Vladimir Cermak et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2020)
Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment
Angela Flavia Serpico et al.
CELL DEATH & DISEASE (2020)
Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma
Vijay M. Patil et al.
CANCER MEDICINE (2020)
DNA damage checkpoint kinases in cancer
Hannah L. Smith et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2020)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Radiosynthesis of microtubule-targeted theranostic methyl N-[5-(3'-radiohalobenzoyl)-1H-benzimidazol-2-yl]carbamates
Zbigniew P. Kortylewicz et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2018)
Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells
K. Canova et al.
TOXICOLOGY IN VITRO (2018)
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Yeon Hee Park et al.
EUROPEAN JOURNAL OF CANCER (2017)
Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases
Matthias Schmidt et al.
MOLECULES (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
Shigeto Maeda et al.
BREAST (2017)
Analysis of mebendazole binding to its target biomolecule by laser flash photolysis
Dolors Jornet et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY (2016)
RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment
A. L. Hein et al.
ONCOGENE (2016)
Safety of Mebendazole Use During Lactation: A Case Series Report
Nour Karra et al.
DRUGS IN R&D (2016)
Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value
Brian David Lehmann et al.
BMC CANCER (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting Microtubules by Natural Agents for Cancer Therapy
Eiman Mukhtar et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Next-generation sequencing in breast cancer: first take home messages
Christine Desmedt et al.
CURRENT OPINION IN ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study
C. Villanueva et al.
EUROPEAN JOURNAL OF CANCER (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
Herve Bonnefoi et al.
LANCET ONCOLOGY (2011)
The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma
Paul A. Spagnuolo et al.
BLOOD (2010)
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer
Mohammad H. Pourgholami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Telomerase-immortalized human mammary stem/progenitor cells with ability to self-renew and differentiate
Xiangshan Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
γ-irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1
Ying Yan et al.
CANCER RESEARCH (2008)
Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5
Jue Shi et al.
CANCER RESEARCH (2008)
DNA damage induces two distinct modes of cell death in ovarian carcinomas
H. Vakifahmetoglu et al.
CELL DEATH AND DIFFERENTIATION (2008)
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
R. Conforti et al.
ANNALS OF ONCOLOGY (2007)
Molecular profling of docetaxel cytotoxicity in breast cancer cells:: uncoupling of aberrant mitosis and apoptosis
H. Hernandez-Vargas et al.
ONCOGENE (2007)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
The p53 tumor suppressor participates in multiple cell cycle checkpoints
Luciana E. Giono et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
DA Berry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation
Y Yan et al.
ONCOGENE (2005)
Pilot study of albendazole in patients with advanced malignancy - Effect on serum tumor markers/high incidence of neutropenia
DL Morris et al.
ONCOLOGY (2001)
分享论文
